Six compounds. Fully documented.
We launched with six SKUs because six is what we can synthesize, test, document, and stand behind on day one. New compounds are added when the documentation can keep up — never sooner.
Every compound, every batch, every COA.
Each card links to the full product page with the latest batch data, the COA PDF, references, and pricing. The page sells one compound. The next page sells the next compound. No upsell carousels.
BPC-157
Body Protection Compound · 15-residue peptide
A synthetic peptide derived from a sequence first identified in human gastric juice. The published research base is overwhelmingly preclinical.
TB-500
Thymosin Beta-4 active fragment
A synthetic peptide containing the active region of Thymosin Beta-4. Mature in vitro literature on actin dynamics; earlier-stage translational work.
GHK-Cu
Glycyl-L-histidyl-L-lysine copper complex
A naturally-occurring tripeptide bound to a copper(II) ion. One of the larger in vitro research bases of any small peptide.
Semax
Synthetic ACTH(4-10) analog · 7-residue peptide
Developed in Russia in the 1980s. Substantial portion of foundational literature is Russian-language; smaller body of independent Western replication.
MOTS-c
Mitochondrial-derived 16-residue peptide
Encoded within the human mitochondrial 12S rRNA gene. Identified in published research from 2015 onward — earlier-stage translational base.
Tirzepatide
Dual GIP / GLP-1 receptor agonist · 39-residue peptide
Synthetic dual incretin-receptor agonist with a C-20 fatty diacid moiety for extended albumin binding. Large clinical literature; established cell-line and receptor-binding base for in vitro work.
The catalog grows when the documentation can keep up.
Every new SKU has to pass internal QC, get an independent third-party COA dated within the launch quarter, and earn a place on the catalog. We expect to add roughly one to two compounds per quarter through the first year — not because the synthesis is hard, but because the verification infrastructure is. Saying no to products is part of the brand.
If there's a compound you'd like to see and we don't carry it, email research@ledgerbioscience.com. We track requests and prioritize the catalog roadmap from them.
Every batch. Every time. No exceptions.
Each batch is synthesized at our named contract synthesis partner, then shipped to an independent lab partner for HPLC and mass spectrometry testing. The full report — chromatogram, peak integration, identity confirmation — is published on the product page with the date, the batch number, and the lab's name on it. If a batch doesn't pass internal QC, it doesn't get a COA. It doesn't get sold. It gets destroyed and logged.
Start with a small order. Verify everything.
Pick a compound. Read the COA. Cross-check the batch number when it arrives.